IVI-RETRACT registry update: recruitment status and timeline revised
Editorial review: not recorded.
Bottom line
ClinicalTrials.gov lists IVI-RETRACT (NCT07481500), a randomized comparison of eyelid speculum and cotton-tipped applicator retraction for intravitreal injections, as active but no longer recruiting. Enrollment is now 129 actual participants, up from 120 estimated; estimated primary completion moved from June 2027 to 7 October 2026. No results are posted.
Trial at a glance
- NCT
- NCT07481500
- Acronym
- IVI-RETRACT
- Sponsor
- Jakkrit Juhong
- Indication
- Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema; Retinal Vein Occlusion; Intravitreal Injections; Polypoidal Choroidal Vasculopathy
- Comparator
- Eyelid Speculum (Group A)
- Registered enrollment
- 129
- Primary endpoints
- Pain Perception — 1-5 minutes after intravitreal injection (Day 0); Procedure Duration — During intravitreal injection procedure (Day 0); Patient Satisfaction — 1-5 minutes after intravitreal injection (Day 0); Procedure-Related Complications — Day 0, Day 1, and Week 4 post-injection
- Recruitment
- Active, not recruiting
- Primary completion
- 2026-10-07
- Last registry update
- 2026-09-25
- Results posted
- No
What changed
- Recruitment
Not yet recruiting→ Active, not recruiting25 Sept 2026 ↗ - Enrollment
120→ 12925 Sept 2026 ↗ - Primary completion
2027-06→ 2026-10-0725 Sept 2026 ↗
Why read it
The registry update gives retina clinicians a clearer view of this trial's progress and planned assessment of pain, procedure duration, satisfaction, and complications.
What this does not prove
These are registry data only. No clinical results are posted, and the enrollment or estimated completion date does not establish comparative outcomes or a practice change.
Original source
Source date: 25 Sept 2026 · Thailand
Report a correction →